Meet the team committed to compassionate action on behalf of those suffering with disabling neuropsychiatric conditions.
Our mission is to develop novel therapies to dramatically improve the lives of people with psychiatric and neurological disorders.
Karuna Therapeutics is bringing together a community of scientists, clinicians, and leaders with deep expertise in neuroscience and drug development.
Stephen Brannan, M.D.
Chief Medical Officer
Andrew Miller, Ph.D.
Founder and Chief Operating Officer
Troy A. Ignelzi
Chief Financial Officer
Giorgio Attardo, Ph.D.
Vice President, CMC and Preclinical Development
Jim Audia, Ph.D.
Head of Medicinal Chemistry and Senior Adviser
Gregory T. Brophy, Ph.D.
Head of Regulatory and Senior Adviser
Vice President of Corporate Finance
Christian Felder, Ph.D.
Vice President, Discovery Research
David Hewitt, M.D.
Senior Vice President, Medical
Jim Monn, Ph.D.
Vice President, Medicinal Chemistry
Advised by world experts in schizophrenia, Alzheimer’s disease, and neuroscience, we are positioned to meaningfully improve the lives of patients by delivering more effective and better tolerated treatments using a completely new mechanism of action (MOA).
Board of Directors
Steve Paul, M.D.
Chairman of the Board, President and Chief Executive Officer
Edmund Harrigan, M.D.
Former SVP, Worldwide Safety & Regulatory, Pfizer, Inc.
Jim Healy, M.D., Ph.D.
General Partner, Sofinnova Investments
Jeff Jonas, M.D.
Chief Executive Officer, Sage Therapeutics
Atul Pande, M.D.
Former Senior Vice President, Head of Neuroscience and Senior Advisor, Pharmaceutical R&D at GlaxoSmithKline; Member, Karuna Therapeutics Scientific Advisory Board
Robert Nelsen, MBA
Co-Founder and Managing Director, Arch Venture Partners
Heather Preston, M.D.
Managing Partner, Pivotal bioVenture Partners